ABEONA THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ABEONA THERAPEUTICS INC. (ABEO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.94 per share for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2021-11-15
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-09-30 was $0.94, a 63.28% decline year-over-year.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-06-30 was $1.22, a 48.31% decline year-over-year.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-09-30 was $2.56, a 22.49% increase year-over-year.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-06-30 was $2.36, a 56.22% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2021-09-30 | $0.94 10-Q · filed 2021-11-15 | $1.44 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $1.22 10-Q · filed 2021-07-28 | $1.59 10-Q · filed 2021-07-28 | |
| 2020-09-30 | $2.56 10-Q · filed 2021-11-15 | $1.99 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $2.36 10-Q · filed 2021-07-28 | $1.92 10-Q · filed 2021-07-28 | |
| 2019-09-30 | $2.09 10-Q · filed 2019-11-12 | $5.14 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $5.39 10-Q · filed 2019-08-09 | $5.37 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $5.29 10-Q · filed 2019-05-10 | ||
| 2018-09-30 | $11.44 10-Q · filed 2019-11-12 | $11.36 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $12.87 10-Q · filed 2019-08-09 | $11.36 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $10.83 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |